DE1923167A1 - Aminosaeureloesung zur intravenoesen Stickstoffzufuhr bei uraemischen Bedingungen und Verfahren zu deren Herstellung - Google Patents
Aminosaeureloesung zur intravenoesen Stickstoffzufuhr bei uraemischen Bedingungen und Verfahren zu deren HerstellungInfo
- Publication number
- DE1923167A1 DE1923167A1 DE19691923167 DE1923167A DE1923167A1 DE 1923167 A1 DE1923167 A1 DE 1923167A1 DE 19691923167 DE19691923167 DE 19691923167 DE 1923167 A DE1923167 A DE 1923167A DE 1923167 A1 DE1923167 A1 DE 1923167A1
- Authority
- DE
- Germany
- Prior art keywords
- moles
- nitrogen
- infusion solution
- mol
- solution according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title claims description 69
- 229910052757 nitrogen Inorganic materials 0.000 title claims description 35
- 238000001990 intravenous administration Methods 0.000 title claims description 6
- 150000001413 amino acids Chemical class 0.000 title description 27
- 238000000034 method Methods 0.000 title description 9
- 239000000243 solution Substances 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 10
- 239000003978 infusion fluid Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004473 Threonine Substances 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- 235000005911 diet Nutrition 0.000 description 14
- 230000037213 diet Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000006368 chronic pyelonephritis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FPVGTPBMTFTMRT-UHFFFAOYSA-L disodium;2-amino-5-[(4-sulfonatophenyl)diazenyl]benzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019233 fast yellow AB Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE625968 | 1968-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1923167A1 true DE1923167A1 (de) | 1969-11-20 |
Family
ID=20268246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691923167 Pending DE1923167A1 (de) | 1968-05-09 | 1969-05-07 | Aminosaeureloesung zur intravenoesen Stickstoffzufuhr bei uraemischen Bedingungen und Verfahren zu deren Herstellung |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | AT297935B (enrdf_load_stackoverflow) |
| BE (1) | BE732561A (enrdf_load_stackoverflow) |
| DE (1) | DE1923167A1 (enrdf_load_stackoverflow) |
| DK (1) | DK124453B (enrdf_load_stackoverflow) |
| ES (1) | ES366965A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2008137A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1261582A (enrdf_load_stackoverflow) |
| NL (1) | NL6907109A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2303463A1 (de) * | 1973-01-18 | 1974-07-25 | Seperic Morat | Emulsionen zur parenteralen ernaehrung und verfahren zu deren herstellung |
| DE2530246A1 (de) * | 1975-07-07 | 1977-01-13 | Fresenius Chem Pharm Ind | L-aminosaeuregemische fuer parenterale oder orale anwendung |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| JPS5536457A (en) * | 1978-09-08 | 1980-03-14 | Ajinomoto Co Inc | Amino acid infusion |
-
1969
- 1969-04-30 AT AT417169A patent/AT297935B/de not_active IP Right Cessation
- 1969-05-06 BE BE732561D patent/BE732561A/xx unknown
- 1969-05-07 FR FR6914667A patent/FR2008137A1/fr not_active Withdrawn
- 1969-05-07 DE DE19691923167 patent/DE1923167A1/de active Pending
- 1969-05-08 ES ES366965A patent/ES366965A1/es not_active Expired
- 1969-05-08 DK DK251169A patent/DK124453B/da unknown
- 1969-05-09 GB GB2387169A patent/GB1261582A/en not_active Expired
- 1969-05-09 NL NL6907109A patent/NL6907109A/xx unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2303463A1 (de) * | 1973-01-18 | 1974-07-25 | Seperic Morat | Emulsionen zur parenteralen ernaehrung und verfahren zu deren herstellung |
| DE2530246A1 (de) * | 1975-07-07 | 1977-01-13 | Fresenius Chem Pharm Ind | L-aminosaeuregemische fuer parenterale oder orale anwendung |
Also Published As
| Publication number | Publication date |
|---|---|
| ES366965A1 (es) | 1971-06-16 |
| BE732561A (enrdf_load_stackoverflow) | 1969-10-16 |
| GB1261582A (en) | 1972-01-26 |
| NL6907109A (enrdf_load_stackoverflow) | 1969-11-11 |
| AT297935B (de) | 1972-04-10 |
| FR2008137A1 (enrdf_load_stackoverflow) | 1970-01-16 |
| DK124453B (da) | 1972-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19748290B4 (de) | Lösung für die Peritonealdialyse | |
| DE3686718T2 (de) | Fluessigkeitstherapie mit 1-laktat- und/oder pyruvat-anionen. | |
| DE3211587A1 (de) | Verwendung einer therapeutischen mischung zur regulierung des koerpergewichtes von menschen und saeugetieren | |
| DE69529213T2 (de) | Verwendung von magnesium enthaltenden verbindungen zur behandlung oder prophylaxe von krebs- und autoimmunkrankheiten | |
| EP0613688A1 (de) | Verfahren zur Bereitung von bicarbonathaltigen Dialysierflüssigkeiten für die Hämodialyse | |
| DE4212640A1 (de) | Betablocker enthaltende, stabile arzneimittelzusammensetzungen mit regulierter wirkstoffabgabe fuer orale verabreichung und verfahren zu ihrer herstellung | |
| EP0002495B1 (de) | Erzeugnisse zur Anwendung in der cytostatischen Therapie | |
| DE3883606T2 (de) | Verwendung von Fluoxetin zur Behandlung des Diabetes. | |
| DE3040780C2 (de) | Verwendung einer pharmazeutischen Zusammensetzung zur Behandlung von Diabetes | |
| DE3115080A1 (de) | Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung | |
| DE2329158A1 (de) | Heilmittel zur behandlung der ketonaemie und der osteomalazie bei vieh, insbesondere hornvieh | |
| DE2335215A1 (de) | Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung | |
| DE1923167A1 (de) | Aminosaeureloesung zur intravenoesen Stickstoffzufuhr bei uraemischen Bedingungen und Verfahren zu deren Herstellung | |
| DE3832401C2 (enrdf_load_stackoverflow) | ||
| DE2750159C3 (de) | Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung | |
| DE102009012671A1 (de) | Plasmaadaptierte Vollelektrolytlösung | |
| DE2759133A1 (de) | Gemisch essentieller aminosaeuren und/oder analoger ketosaeuren und verwendung derselben diaetzusatz bei niereninsuffizienz | |
| DE2013426A1 (en) | Zinc chelates of amino acids in diabetes | |
| DE2743704C2 (de) | L- oder DL-Phenylglycine enthaltende Arzneimittel | |
| DE3115322A1 (de) | Oral zu verabreichendes, pharmazeutisch bzw. diagnostisch oder als nahrungsmittelzusatz wirksames bzw. verwendbares mittel | |
| EP0334177B1 (de) | Oral verabreichbares pharmazeutisches Mittel, insbesondere zur Eisen- und Magnesiumsubstitutionstherapie | |
| DE2349186C2 (de) | Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion | |
| DE4100361C1 (enrdf_load_stackoverflow) | ||
| DE102023001399B4 (de) | Aminosäurenkombination mit Vitaminen, Mineralien und Spurenelementen zur kurativen und rehabilitativen Behandlung von Post-COVID-Syndrom, Post-COVID-19-Syndrom undPost-Vaccine-Syndrom. | |
| DE2633948A1 (de) | Infusionsloesung fuer die intravenoese ernaehrung und verfahren zu ihrer herstellung |